Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes.
Storer RI, Pike A, Swain NA, Alexandrou AJ, Bechle BM, Blakemore DC, Brown AD, Castle NA, Corbett MS, Flanagan NJ, Fengas D, Johnson MS, Jones LH, Marron BE, Payne CE, Printzenhoff D, Rawson DJ, Rose CR, Ryckmans T, Sun J, Theile JW, Torella R, Tseng E, Warmus JS. Storer RI, et al. Among authors: pike a. Bioorg Med Chem Lett. 2017 Nov 1;27(21):4805-4811. doi: 10.1016/j.bmcl.2017.09.056. Epub 2017 Sep 28. Bioorg Med Chem Lett. 2017. PMID: 29029933
The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1.
Tran TD, Wakenhut F, Pickford C, Shaw S, Westby M, Smith-Burchnell C, Watson L, Paradowski M, Milbank J, Brimage RA, Halstead R, Glen R, Wilson CP, Adam F, Hay D, Chiva JY, Nichols C, Blakemore DC, Gardner I, Dayal S, Pike A, Webster R, Pryde DC. Tran TD, et al. Among authors: pike a. ChemMedChem. 2014 Jul;9(7):1378-86. doi: 10.1002/cmdc.201400045. Epub 2014 Apr 11. ChemMedChem. 2014. PMID: 24729513
The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2.
Wakenhut F, Tran TD, Pickford C, Shaw S, Westby M, Smith-Burchnell C, Watson L, Paradowski M, Milbank J, Stonehouse D, Cheung K, Wybrow R, Daverio F, Crook S, Statham K, Leese D, Stead D, Adam F, Hay D, Roberts LR, Chiva JY, Nichols C, Blakemore DC, Goetz GH, Che Y, Gardner I, Dayal S, Pike A, Webster R, Pryde DC. Wakenhut F, et al. Among authors: pike a. ChemMedChem. 2014 Jul;9(7):1387-96. doi: 10.1002/cmdc.201400046. Epub 2014 Apr 11. ChemMedChem. 2014. PMID: 24729518
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.
Swain NA, Batchelor D, Beaudoin S, Bechle BM, Bradley PA, Brown AD, Brown B, Butcher KJ, Butt RP, Chapman ML, Denton S, Ellis D, Galan SRG, Gaulier SM, Greener BS, de Groot MJ, Glossop MS, Gurrell IK, Hannam J, Johnson MS, Lin Z, Markworth CJ, Marron BE, Millan DS, Nakagawa S, Pike A, Printzenhoff D, Rawson DJ, Ransley SJ, Reister SM, Sasaki K, Storer RI, Stupple PA, West CW. Swain NA, et al. Among authors: pike a. J Med Chem. 2017 Aug 24;60(16):7029-7042. doi: 10.1021/acs.jmedchem.7b00598. Epub 2017 Aug 10. J Med Chem. 2017. PMID: 28682065
Physiology of Hyperuricemia and Urate-Lowering Treatments.
Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI, Vangjeli C. Benn CL, et al. Among authors: pike a. Front Med (Lausanne). 2018 May 31;5:160. doi: 10.3389/fmed.2018.00160. eCollection 2018. Front Med (Lausanne). 2018. PMID: 29904633 Free PMC article. Review.
Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865).
Owen RM, Blakemore D, Cao L, Flanagan N, Fish R, Gibson KR, Gurrell R, Huh CW, Kammonen J, Mortimer-Cassen E, Nickolls SA, Omoto K, Owen D, Pike A, Pryde DC, Reynolds DS, Roeloffs R, Rose C, Stead C, Takeuchi M, Warmus JS, Watson C. Owen RM, et al. Among authors: pike a. J Med Chem. 2019 Jun 27;62(12):5773-5796. doi: 10.1021/acs.jmedchem.9b00322. Epub 2019 Apr 26. J Med Chem. 2019. PMID: 30964988
Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Grimster NP, Gingipalli L, Barlaam B, Su Q, Zheng X, Watson D, Wang H, Simpson I, Pike A, Balazs A, Boiko S, Ikeda TP, Impastato AC, Jones NH, Kawatkar S, Kemmitt P, Lamont S, Patel J, Read J, Sarkar U, Sha L, Tomlinson RC, Wang H, Wilson DM, Zehnder TE, Wang L, Wang P, Goldberg FW, Shao W, Fawell S, Dry H, Dowling JE, Edmondson SD. Grimster NP, et al. Among authors: pike a. Bioorg Med Chem Lett. 2020 Oct 1;30(19):127433. doi: 10.1016/j.bmcl.2020.127433. Epub 2020 Jul 24. Bioorg Med Chem Lett. 2020. PMID: 32717371
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Kawatkar SP, Barlaam B, Kemmitt P, Simpson I, Watson D, Wang P, Lamont S, Su Q, Boiko S, Ikeda T, Patel J, Pike A, Pollard H, Read J, Sarkar U, Wang H, Wen Q, Yan Z, Dowling JE, Dry H, Edmondson SD. Kawatkar SP, et al. Among authors: pike a. Bioorg Med Chem Lett. 2020 Sep 15;30(18):127393. doi: 10.1016/j.bmcl.2020.127393. Epub 2020 Jul 10. Bioorg Med Chem Lett. 2020. PMID: 32721854
472 results